title: Regression of pulmonary MALT lymphoma after treatment with rituximab.
abstract: We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 months after finishing her treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma.
authors.affiliation: Hematology-Oncology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Elise A
authors.initials: EA
authors.lastname: Chong
authors.forename: Jakub
authors.initials: J
authors.lastname: Svoboda
authors.forename: Sindhu
authors.initials: S
authors.lastname: Cherian
authors.forename: Charalambos
authors.initials: C
authors.lastname: Andreadis
authors.forename: Lisa H
authors.initials: LH
authors.lastname: Downs
authors.forename: Hongming
authors.initials: H
authors.lastname: Zhuang
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi
authors.forename: Donald E
authors.initials: DE
authors.lastname: Tsai
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab